Latest Commercial Rollout News

Imricor Medical Systems has taken a significant step toward US market entry by submitting its Advantage-MR EP Recorder/Stimulator system for FDA 510(k) clearance, aiming to enhance MRI-guided cardiac procedures.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Sparc Technologies and the Australian Institute for Machine Learning are developing AI-driven software to transform protective coatings corrosion assessment, promising faster, more accurate results for a global market of testing labs.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

EVE Health Group has transitioned from development to commercial rollout, delivering first patient prescriptions of Dyspro™ and completing initial manufacturing of Libbo™, supported by a $1.1 million capital raise.

4DMedical Limited has responded to ASX queries over its announcements of commercial agreements with leading US academic medical centres, clarifying its disclosure approach and denying ramping allegations ahead of a $150 million capital raise.

Klevo Rewards Ltd has successfully reinstated its ASX listing, completed a $3.4 million capital raise, and made significant progress on its digital wallet and loyalty platform. The company’s improved cash position and operational momentum set the stage for its next growth phase.

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.

EVE Health Group has completed manufacturing and distribution setup for Libbo™, its innovative oral dissolving film for erectile dysfunction, paving the way for near-term patient access via telehealth and pharmacy channels.

Swift TV Limited has reported robust Q2 activity with over 4,300 devices pre-sold, including a significant 2,000-device order from Chevron, positioning the company for a commercial rollout in Q3 FY26.

Skin Elements Limited has marked a pivotal quarter with a $2.5 million capital raise and successful product evaluations, setting the stage for commercial rollout of its natural biotechnology range in 2026.

Decidr AI Industries has solidified its position in the agentic AI market by completing strategic acquisitions and launching its DecidrOS platform, achieving a 60% revenue increase in the December quarter.